Koers Novus Therapeutics, Inc. Nasdaq
Aandelen
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | - | Omzet 2025 * | 33,33 mln. 31,17 mln. | Marktkapitalisatie | 97,81 mln. 91,46 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -47 mln. -43,95 mln. | Nettowinst (verlies) 2025 * | -33 mln. -30,86 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 2,93 x |
K/w-verhouding 2024 * |
-2,01
x | K/w-verhouding 2025 * |
-4,17
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 96,49% |
Recentste transcriptie over Novus Therapeutics, Inc.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 51 | 01-05-20 | |
Paul Little
DFI | Director of Finance/CFO | 60 | 15-03-21 |
Steven Perrin
PSD | President | 59 | 14-09-20 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Keith Katkin
CHM | Chairman | 52 | 01-05-17 |
Walter Ogier
BRD | Director/Board Member | 67 | 14-09-20 |
John McBride
BRD | Director/Board Member | 72 | 01-05-17 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+16,13% | 122 mld. | |
+19,65% | 115 mld. | |
+21,22% | 26,64 mld. | |
-23,84% | 19,91 mld. | |
-17,47% | 16,32 mld. | |
-45,95% | 15,52 mld. | |
-19,28% | 15,49 mld. | |
+63,81% | 14,83 mld. | |
+1,94% | 13,67 mld. |